On the importance and challenges of global access to proven life-saving treatments for Ebolavirus

Lancet Infect Dis. 2023 Apr;23(4):406-407. doi: 10.1016/S1473-3099(23)00141-X.

Authors

Olivier Tshiani Mbaya¹, Placide Mbala Kingebeni², Lori E Dodd³, Jean-Jacques Muyembe Tamfum², Clifford Lane³

Affiliations

¹ Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. Electronic address: olivier.tshianimbaya@nih.gov.
² Institut National de Recherche Biomédicale, Kinshasa, Democratic Republic of Congo.
³ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.

PMID: 36963916
DOI: 10.1016/S1473-3099(23)00141-X

No abstract available

Publication types

Letter
Comment

MeSH terms

Ebolavirus*
Hemorrhagic Fever, Ebola* / drug therapy
Hemorrhagic Fever, Ebola* / epidemiology
Humans